Release Date: 05/18/2022
Expiration Date: 05/18/2023
*Please note that you must complete the Post Webinar Evaluation (link below) to receive CE credit.
Kirk Cumpston, DO, FAACT
Professor of Emergency Medicine
Medical Director, Virginia Poison Center
Associate Fellowship Director, Medical Toxicology Fellowship
Richard Chen, MD
Division of Medical Toxicology
Department of Emergency Medicine
Albert Einstein Medical Center
Gina Stassinos, PharmD, DABAT
Clinical Pharmacist – Emergency Department
Assistant Clinical Professor
UC San Francisco Medical Center
UCSF, School of Pharmacy
Shawn M. Varney, MD, FAACT, FACEP, FACMT
Professor of Emergency Medicine
Medical Director, South Texas Poison Center
University of Texas Health Science Center San Antonio
Recognized since the 1960’s, serotonin syndrome is a condition that occus in patients taking proserotonergic medications/substances and is characterized by altered mental status, neuromuscular abnormalities, and autonomic dysfunction, including hyperthermia. The clinical findings occur on a continuum, and thus may mimic other pathologies. Medical and clinical toxicologists are expected to understand drug-drug interactions and clinical scenarios with the potential for serotonin toxicity. Using an interactive journal club discussion format, this webinar will describe the mechanism of toxicity for serotonin syndrome including gradient of toxicity by receptors. It will discuss which drugs DO NOT cause a serotonin toxidrome but have been wrongfully implicated, as well as outline which drugs are strongly associated with serotonin toxidrome. Finally, it will discuss the strengths and weaknesses of diagnostic criteria and modified criteria for serotonin syndrome.
Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.
Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Physicians and Pharmacists
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and American Academy of Clinical Toxicology. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM for physicians and 1 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.
Objectives – After attending this program you should be able to:
- Describe the mechanism of toxicity for serotonin syndrome including gradient of toxicity by receptors
2. Discuss which drugs DO NOT cause a serotonin toxidrome but have been wrongfully implicated
3. Outline which drugs are strongly associated with serotonin toxidrome
4. Discuss the strengths and weaknesses of diagnostic criteria, and modified criteria, for serotonin syndrome
Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-‐6.2, 6.5)
Enduring UAN: JA4008163-9999-22-119-H04-P